Short-Term, High-Dose Atorvastatin Pretreatment to Prevent Contrast-Induced
Nephropathy in Patients With Acute Coronary Syndromes Undergoing Percutaneous
Coronary Intervention (from the ARMYDA-CIN [Atorvastatin for Reduction of
MYocardial Damage during Angioplasty-Contrast-Induced Nephropathy] Trial.
Patti G, et al; Am J Cardiol. 2011 Apr …